| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,400 | 16,500 | 15.05. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.05. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 327 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 23.04. | Sartorius Stedim Biotech S.A. GAAP EPS of €0.91, revenue of €761.5M | 3 | Seeking Alpha | ||
| 23.04. | Sartorius Stedim Biotech SA Q1 Profit Rises | 354 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech SA (DIM.PA) released earnings for its first quarter that Increases, from the same period last yearThe company's bottom line came in at EUR88.1 million... ► Artikel lesen | |
| 23.04. | Sartorius Stedim Biotech Q1 Profit Rises On Revenue Growth; Confirms FY26 Outlook | 328 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech SA (SDMHF) reported Thursday higher profit and revenues in its first quarter. Further, the firm maintained its fiscal 2026 outlook.René Fáber, CEO... ► Artikel lesen | |
| 23.04. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026 | 460 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Quarter Results
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026 23-Apr-2026 / 07:00 CET/CEST
Aubagne... ► Artikel lesen | |
| 02.04. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 371 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 01.04. | Dividendenbekanntmachungen (01.04.2026) | 9.022 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECOM US00766T1007 0,31 USD 0,2683 EUR AIR PRODUCTS & CHEMICALS INC US0091581068 1,81 USD 1,5666 EUR ARB CORPORATION LIMITED AU000000ARB5 0... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH SA ADR Aktie jetzt für 0€ handeln | |||||
| 24.03. | Sartorius Stedim Biotech SA: Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. | 575 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. 24-March-2026 / 15:32 CET/CEST
Aubagne... ► Artikel lesen | |
| 17.03. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets | 697 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Forecast
Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets 17-March-2026 / 07:03... ► Artikel lesen | |
| 02.03. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 504 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 16.02. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech releases Universal Registration Document 2025 | 665 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2025 16-Feb-2026 / 09:13 CET/CEST
Aubagne, France... ► Artikel lesen | |
| 06.02. | Board of Directors of Sartorius Stedim Biotech S.A. resolves dividend proposal of 0.69 euros | 527 | Dow Jones News | DJ Board of Directors of Sartorius Stedim Biotech S.A. resolves dividend proposal of 0.69 euros
Sartorius Stedim Biotech SA / Key word(s): Dividend
Board of Directors of Sartorius Stedim Biotech... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech FY25 Results Climb; Sees Growth In FY26, Beyond | 521 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech S.A. (SRTOY, SDMHF, DIM.PA) reported Tuesday higher profit and sales revenues in fiscal 2025, with growth in all regions. Looking ahead for fiscal... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook | 934 | Dow Jones News | DJ Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook
Sartorius Stedim Biotech SA / Key word(s): Preliminary Results
Sartorius Stedim Biotech... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech S.A. Non-GAAP EPS of €4.40, revenue of €2.97B; initates FY26 outlook | 4 | Seeking Alpha | ||
| 02.02. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 399 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 12.01. | Goldman Sachs stuft Sartorius Stedim Biotech nach Kursrallye herab | 5 | Investing.com Deutsch | ||
| 12.01. | Goldman Sachs downgrades Sartorius Stedim Biotech stock rating after recent rally | 3 | Investing.com | ||
| 06.01. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 963 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 05.01. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 536 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,465 | -0,44 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,560 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| HCW BIOLOGICS | 1,210 | -0,82 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,09 | -0,06 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| PRAXIS PRECISION MEDICINES | 341,89 | -0,20 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 66,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| EVOTEC | 4,618 | -1,74 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| BIONTECH | 76,40 | -2,98 % | BioNTech-Krise vs. Emyria-Durchbruch? Warum Daten jetzt die Forschung schlagen | ||
| COGENT BIOSCIENCES | 32,710 | +0,09 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| NUVALENT | 102,40 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| JADE BIOSCIENCES | 23,355 | 0,00 % | Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,205 | +0,04 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TYRA BIOSCIENCES | 37,070 | +0,08 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| KYMERA THERAPEUTICS | 82,25 | +0,05 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| BEAM THERAPEUTICS | 27,945 | +0,05 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |